Testing metformin with two newer diabetes drugs
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial is testing if adding a combination of SGLT-2 inhibitor and GLP-1 receptor agonist to metformin can improve blood sugar control in people with type 2 diabetes who are not meeting their goals on metformin alone or with one other pill.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes and are between 18 and 75 years old.
- Your body mass index (BMI) is 20 or higher.
- You have been taking at least 1000 mg of metformin daily for 8 weeks or more, with or without one other diabetes pill (but not an SGLT-2i or oral GLP-1RA).
- Your average blood sugar over 2–3 months (HbA1c) is between 7.5% and 11.0%.
- You have not used insulin in the past week, or GLP-1RA or SGLT-2i drugs in the past 12 weeks.
- You do not have serious kidney, liver, or pancreas problems, and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three diabetes medicines (henagliflozin, retagliptin, and extended-release metformin) to see if they are safe and effective for Chinese adults with type 2 diabetes. You may join if you are newly diagnosed or have been taking one oral diabetes pill but need better blood sugar control.
This study compares two versions of a combination medication (chiglitazar and metformin) to ensure they work the same way in the body. Researchers are recruiting healthy volunteers to help determine if the new formulation is equivalent to the standard version.
This trial is testing a combination of three diabetes medicines (henagliflozin, retagliptin, and metformin) in people newly diagnosed with type 2 diabetes. The goal is to see if this triple therapy works better for controlling blood sugar compared to standard treatments.
This study looks at the safety and effectiveness of adding a third oral diabetes medicine to your current two-drug combination. It is for adults with type 2 diabetes whose blood sugar is not well controlled on metformin plus one other pill.
This trial compares adding a new pill (cofrogliptin) to increasing your current metformin dose, for people whose blood sugar is still too high despite taking an SGLT2 inhibitor and a low dose of metformin. The goal is to see which option works better and is safer.
This study tests a combination of three diabetes medicines (empagliflozin, linagliptin, and metformin) to see if it helps control blood sugar in people with type 2 diabetes. It may be an option if your current treatment isn't working well enough.
Hear when a new T2DM (Type 2 Diabetes Mellitus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.